These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32514196)

  • 61. Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand.
    Kamolratanakul P; Hiransuthikul N; Singhadong N; Kasetjaroen Y; Akksilp S; Lertmaharit S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):321-30. PubMed ID: 12236432
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effective control of drug-resistant TB: listening to other voices.
    Portero JL; Rubio M
    PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207
    [No Abstract]   [Full Text] [Related]  

  • 64. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens.
    Eshetie S; Alebel A; Wagnew F; Geremew D; Fasil A; Sack U
    BMC Infect Dis; 2018 Sep; 18(1):486. PubMed ID: 30261852
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.
    Loveday M; Wallengren K; Reddy T; Besada D; Brust JCM; Voce A; Desai H; Ngozo J; Radebe Z; Master I; Padayatchi N; Daviaud E
    PLoS One; 2018; 13(4):e0196003. PubMed ID: 29668748
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
    Ismail NA; Mvusi L; Nanoo A; Dreyer A; Omar SV; Babatunde S; Molebatsi T; van der Walt M; Adelekan A; Deyde V; Ihekweazu C; Madhi SA
    Lancet Infect Dis; 2018 Jul; 18(7):779-787. PubMed ID: 29685458
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
    J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 73. How affordable is TB care? Findings from a nationwide TB patient cost survey in Ghana.
    Pedrazzoli D; Siroka A; Boccia D; Bonsu F; Nartey K; Houben R; Borghi J
    Trop Med Int Health; 2018 Aug; 23(8):870-878. PubMed ID: 29851223
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review.
    Thomas BE; Shanmugam P; Malaisamy M; Ovung S; Suresh C; Subbaraman R; Adinarayanan S; Nagarajan K
    PLoS One; 2016; 11(1):e0147397. PubMed ID: 26807933
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Examining the cost of community-based tuberculosis treatment in South Africa.
    Moran A; Kula N; Jagwer G; Broughton E; Pillay Y; Mvusi L; AlMossawi H; Ndjeka N; Mametja D; Dlamini C; Ahmedov S; Matji R; Kak N
    Int J Tuberc Lung Dis; 2020 Jun; 24(6):612-618. PubMed ID: 32552992
    [No Abstract]   [Full Text] [Related]  

  • 77. Cost of managing severe cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa.
    Knight LK; Lehloenya RJ; Sinanovic E; Pooran A
    Trop Med Int Health; 2019 Aug; 24(8):994-1002. PubMed ID: 31173430
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
    Chem ED; Van Hout MC; Hope V
    BMC Infect Dis; 2019 Aug; 19(1):723. PubMed ID: 31420021
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
    Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A
    Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
    Haley CA; Macias P; Jasuja S; Jones BA; Rowlinson MC; Jaimon R; Onderko P; Darnall E; Gomez ME; Peloquin C; Ashkin D; Goswami ND
    Emerg Infect Dis; 2021 Jan; 27(1):332-4. PubMed ID: 33227229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.